Effect of cimetidine on renal and hepatic drug elimination: studies with triamterene

Clinical Pharmacology and Therapeutics
M R MuirheadF Bochner

Abstract

A chronic-dosing pharmacokinetic study was carried out in six healthy subjects to examine the potential for cimetidine to reduce the CLR and CLH of triamterene. Blood and urine samples were collected frequently for 24 hours after dosing with triamterene alone (100 mg/day) for 4 days and concomitant cimetidine (400 mg twice daily) for an additional 4 days. Cimetidine significantly reduced the clearance of triamterene by hydroxylation by 32% (P less than 0.016) and the CLR of triamterene by 28% (P less than 0.063), with no change in its protein binding. The CLR of the active sulfate conjugate of triamterene was not altered by cimetidine. There was a reduced recovery of triamterene and its metabolites in urine after cimetidine, suggesting a decreased absorption. These results are consistent with cimetidine inhibiting cytochrome P-450 enzymes in the liver and also competing with triamterene for renal tubular secretion. Despite the pharmacokinetic interaction, cimetidine caused minimal alteration to the natriuretic and antikaliuretic effects of triamterene.

Citations

Feb 1, 1989·DICP : the Annals of Pharmacotherapy·T Kosoglou, P H Vlasses
Jun 1, 1989·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·M R MuirheadF Bochner
Aug 1, 1988·Journal of Clinical Pharmacology·A A Somogyi, F Bochner
Jan 24, 2009·The Journal of Pharmacology and Experimental Therapeutics·Masahiro TsudaKen-ichi Inui
Jan 1, 1990·British Journal of Clinical Pharmacology·A SomogyiF Bochner
Jan 1, 1994·International Archives of Occupational and Environmental Health·J W Edwards, B G Priestly
Jan 5, 2002·Drug Metabolism Reviews·R Masereeuw, F G Russel
Jan 1, 1997·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals· Mansur R Azari Faith M Williams Peter G Blain John W Edwards
May 1, 1992·Human & Experimental Toxicology·J W Edwards, B G Priestly
Feb 1, 1993·British Journal of Industrial Medicine·J W Edwards, B G Priestly
Jan 12, 2001·Clinical and Experimental Pharmacology & Physiology·L C StrindeliusK M Corbett
Feb 18, 2017·Clinical Pharmacokinetics·Anton IvanyukThierry Buclin
Jan 1, 1987·European Journal of Clinical Pharmacology·A Somogyi, M Muirhead
May 1, 1987·British Journal of Clinical Pharmacology·A SomogyiF Bochner
Mar 11, 1998·Clinical and Experimental Pharmacology & Physiology·R L NationP H Hsyu
Jan 18, 2002·Antimicrobial Agents and Chemotherapy·F De BonyP Rolan
Jan 1, 1991·Alimentary Pharmacology & Therapeutics·P D Hansten

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.